ALIVUS - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 3.8

📊 Analysis: ALIVUS trades at ₹901, slightly below its DMA 50 (₹909) and DMA 200 (₹963), showing mild weakness. RSI at 50.7 is neutral, while MACD (-3.53) signals minor bearish momentum. Strong fundamentals (ROCE 24.9%, ROE 18.7%) and quarterly profit growth (+36.4%) support confidence. Liquidity is adequate (96K vs 76K avg volume). Intraday trading is possible with cautious positioning near support.

• 💹 Optimal Buy Price: ₹895–905 (near current support zone)
• 🎯 Profit-Taking Levels: ₹920 (first resistance), ₹940 (next resistance)
• 🛡️ Stop-Loss: Below ₹885 (to protect against breakdown)
• ⏱️ Exit if Holding: Exit intraday if price fails to sustain above ₹895 or if RSI slips below 48 with MACD turning more negative despite volume support.

Positive

• ✅ Strong ROCE 24.9% and ROE 18.7% reflect efficient capital use.
• ✅ Quarterly profit growth (+36.4%) shows operational strength.
• ✅ Low debt-to-equity 0.02 ensures financial stability.
• ✅ FII holding increased (+0.42%), showing foreign investor confidence.

Limitation

• ⚠️ Price below DMA 50 & 200, indicating short-term weakness.
• ⚠️ MACD negative (-3.53), showing mild bearish momentum.
• ⚠️ PEG ratio 4.42 suggests expensive growth valuation.
• ⚠️ DII holding reduced (-0.15%), showing domestic investor caution.

Company Negative News

• ❌ Technical weakness with price trading below key moving averages.
• ❌ Valuation concerns with PEG ratio above fair levels.

Company Positive News

• 🌟 Profit growth from ₹122 Cr. to ₹130 Cr. in latest quarter.
• 🌟 Strong efficiency metrics (ROCE, ROE) support long-term fundamentals.

Industry

• 🏗️ Industry PE at 30.6 vs ALIVUS PE 20.8 shows relative undervaluation.
• 🏗️ Sector outlook remains stable, offering defensive opportunities for investors.

Conclusion

📌 ALIVUS is a moderate intraday candidate with strong fundamentals but mild technical weakness. Traders may attempt quick scalps near ₹895–905 with profit exits around ₹920–940, while maintaining a disciplined stop-loss below ₹885.

Would you like me to extend this into a sector basket overlay with peer benchmarking so you can compare ALIVUS against other mid-cap pharma and healthcare stocks for intraday rotation opportunities?